Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests

Abstract

In patients with early-stage endocrine receptor-positive (ER+) breast cancer (BC), adjuvant endocrine therapy (ET) for 5 years is the standard of care. However, for some patients, the risk of recurrence remain high for up to 15 years after diagnosis and extended ET beyond 5 years may be a reasonable option. Nevertheless, this strategy significantly increases the occurrence of side effects. Here we summarize the available evidence from randomized clinical trials on the efficacy and safety profile of extended ET and discuss available clinical and genomic tools helpful to select eligible patients in daily clinical practice.

Suppression of miRs-497/195 axis possibly confers endocrine therapy resistance via elevated expression of FLT4 and the noncoding RNA MIR503HG

“…Several genetic tests such as Oncotype Dx, EndoPredict, and MammaPrint provide the risk of recurrence scores and many studies have developed gene signatures associated with TAM, Fulvestrant, and ETR in breast cells and cell line xenografts via transcriptome analysis (5)(6)(7)(8)(9). Few of these signatures have been adapted in the clinic to estimate ETR because rarely do tumors display inherent resistance.…”